Akili, Inc.

Akili, Inc. (Nasdaq: DNAA) is a digital therapeutics company that reached public markets through a SPAC merger with Social Capital Suvretta Holdings Corp. I, a blank-check vehicle sponsored by Social Capital and Suvretta Capital Management that completed its initial public offering in 2021. The de-SPAC business combination closed in August 2022, making Akili one of the first prescription digital therapeutics companies to list via a special purpose acquisition company. Operating in the healthcare technology sector, Akili develops software-based cognitive treatments, including its FDA-authorized EndeavorRx platform targeting pediatric ADHD. The company filed this 8-K with the SEC on May 29, 2024, disclosing material corporate developments. Visit SpacDesk and sign up for full data, filings, and real-time alerts on Akili and the broader SPAC universe.